Anticancer Activity of Tetrahydrocorysamine against Pancreatic Adenocarcinoma Cell Line PANC-1 In vitro and In vivo
Abstract
Purpose: To investigate the cytotoxic activity of tetrahydrocorysamine (TCSM) from Corydalis Rhizoma W. T. Wang (Papaveraceae) against PANC-1 cells and its possible mechanisms.
Methods: TCSM was isolated from Corydalis Rhizoma by column chromatography and identified by mass spectrometry and nuclear magnetic resonance (NMR). The effects of TCSM on the proliferation and apoptosis of PANC-1 cells were determined by methyl thiazolyl tetrazolium (MTT) and flow cytometry assays. The effect of TCSM on the expressions of mitochondria-mediated apoptotic proteins were investigated by Western blot assay. Xenograft assay was used to evaluate the anticancer activity of TCSM in vivo.
Results: TCSM showed cytotoxic activity against PANC-1 cells with half-maximal concentration (IC50) of 19.16 μM in MTT assay. TCSM (5, 10 and 20 μM) significantly (p < 0.01) increased the apoptosis rates of PANC-1 cells (24.45, 35.26 and 54.16 vs 6.12 %), compared with control group. The results of Western blot suggest that TCSM significantly (p < 0.01) down-regulated the expressions of antiapoptotic proteins (Bcl-2 and Survivin), up-regulated the expressions of pro-apoptotic proteins (Bax, Smac, c-caspase-3 and c-caspase-9) and promoted the release of cytochrome C from mitochondria to the cytoplasm of PANC-1 cells, compared with control. TCSM (20 mg/kg) significantly (p < 0.01) inhibited the growth of PANC-1 cell-induced tumor (384 vs 1138 mm3) by regulating the expressions of mitochondria-mediated apoptotic proteins as stated above for xenograft assay, compared with control.
Conclusion: TCSM induces apoptosis in PANC-1 cells in vitro and in vivo via mitochondria-mediated apoptotic pathway.
Keywords: Corydalis Rhizoma, Tetrahydrocorysamine, PANC-1 cells, Flow cytometry, Western blot, Xenograft
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
